GB1516642A - Biological reagent - Google Patents
Biological reagentInfo
- Publication number
- GB1516642A GB1516642A GB24660/74A GB2466074A GB1516642A GB 1516642 A GB1516642 A GB 1516642A GB 24660/74 A GB24660/74 A GB 24660/74A GB 2466074 A GB2466074 A GB 2466074A GB 1516642 A GB1516642 A GB 1516642A
- Authority
- GB
- United Kingdom
- Prior art keywords
- group
- macromolecule
- formula
- free amino
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 229920002521 macromolecule Polymers 0.000 abstract 4
- 150000003180 prostaglandins Chemical class 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 2
- IBOFVQJTBBUKMU-UHFFFAOYSA-N 4,4'-methylene-bis-(2-chloroaniline) Chemical compound C1=C(Cl)C(N)=CC=C1CC1=CC=C(N)C(Cl)=C1 IBOFVQJTBBUKMU-UHFFFAOYSA-N 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- 239000004411 aluminium Substances 0.000 abstract 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000012888 bovine serum Substances 0.000 abstract 1
- 239000001506 calcium phosphate Substances 0.000 abstract 1
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
- 235000011010 calcium phosphates Nutrition 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 abstract 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000002480 mineral oil Substances 0.000 abstract 1
- 235000010446 mineral oil Nutrition 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1516642 Pharmaceutical preparations WELLCOME FOUNDATION Ltd 4 June 1975 [4 June 1974 13 Dec 1974] 24660/74 and 53986/74 Heading A5B [Also in Division C3] A pharmaceutical formulation suitable for parenteral administration in the prophylaxis or therapy in man of a pathological condition in which endogenous prostaglandins are involved comprises an effective prophylactic or therapeutic amount of a conjugate of formula: in which (M) is that part of the macromolecule other than the reactive free amino group of an immunogenic macromolecule containing a reactive free amino group of formula (M)-NH 2 ; (PG) is that part of the molecule other than the terminal carboxy group of a prostaglandin or analogue thereof of formula (PG)-COOH, selected from prostaglandins of the A, B, D and E series and those analogues thereof wherein there is retained the characteristic cyclopentane or cyclopentene group or wherein this group is replaced by a cyclohexane group; Y is selected from (1) -NH(CH 2 ) a NH- where a is 2 to 6 (2) -NH(CH 2 ) b 1 . Z . (CH 2 ) b 2 . NH- where b<SP>1</SP> and b<SP>2</SP> are the same or different and each is 1 to 4 and Z is -O-, -NH- or -CH(OH)-; (3) -W . CO . CH 2 . W<SP>1</SP>- where W and W<SP>1</SP> are the same or different and each group is as defined in -(1) or -(2) above; and (4) -NH . CH 2 . CONH. CH 2 . CO . W<SP>2</SP>- where W<SP>2</SP> is a group defined in (1) or (2) above; x is 2 to 4; m is at least 1 and is not greater than the number of free amino groups in the parent macromolecule of the group (M) available for acylation; p is 0 or 1; and n is 0 or an integer not greater than the number of carboxyl groups in the parent macromolecule of the group (M) available for reaction with the bis-amine H-Y-H, and is 0 when p is 0; and where, when the sum of m and n is greater than 1 the groups (PG) may be the same or different, together with an adjuvant therefor. Examples describe the preparation of bovine serum albumen PGE 1 conjugate and conjugation of prostaglandin PGE 1 with DAP-Suc-B5A. Suitable adjuvants are aqueous solutions, aluminium or calcium salts e.g. potash alum and calcium phosphate, a vegetable oil or a mineral oil.
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB24660/74A GB1516642A (en) | 1974-06-04 | 1974-06-04 | Biological reagent |
| DE19752524637 DE2524637A1 (en) | 1974-06-04 | 1975-06-03 | BIOLOGICAL REAGENTS, METHOD OF MANUFACTURING AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM |
| BE156996A BE829828A (en) | 1974-06-04 | 1975-06-03 | AGENT EXERCISING A BIOLOGICAL ACTIVITY |
| SU752142156A SU639421A3 (en) | 1974-06-04 | 1975-06-03 | Method of obtaining e-series prostaglandine preparation possessing anti-inflammatory effect |
| AU81801/75A AU8180175A (en) | 1974-06-04 | 1975-06-03 | Biological reagent |
| IL47412A IL47412A0 (en) | 1974-06-04 | 1975-06-03 | Prostaglandin conjugates,their preparation and pharmaceutical compositions containing them |
| JP50066961A JPS519714A (en) | 1974-06-04 | 1975-06-03 | |
| SE7506313A SE7506313L (en) | 1974-06-04 | 1975-06-03 | WAY TO PRODUCE A PROSTAGLAND COUNTRY CONJUGATE |
| ZA3568A ZA753568B (en) | 1974-06-04 | 1975-06-03 | Biological reagent |
| US05/583,458 US4110432A (en) | 1974-06-04 | 1975-06-03 | Conjugates of prostaglandins, analogs, formulations and their use |
| FI751633A FI751633A (en) | 1974-06-04 | 1975-06-03 | |
| CH713175A CH614221A5 (en) | 1974-06-04 | 1975-06-03 | |
| FR7517238A FR2273554A1 (en) | 1974-06-04 | 1975-06-03 | PROSTAGLANDIN DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES |
| NL7506560A NL7506560A (en) | 1974-06-04 | 1975-06-03 | METHOD OF PREPARING CONJUGATED PROSTAGLANDINS. |
| DK248775A DK248775A (en) | 1974-06-04 | 1975-06-03 | PROCEDURE FOR PREPARING CONJUGATES OF PROSTAGLANDINS AND PROSTAGLANDIN ANALOG |
| ES438163A ES438163A1 (en) | 1974-06-04 | 1975-06-03 | Conjugates of prostaglandins, analogs, formulations and their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB24660/74A GB1516642A (en) | 1974-06-04 | 1974-06-04 | Biological reagent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1516642A true GB1516642A (en) | 1978-07-05 |
Family
ID=10215227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB24660/74A Expired GB1516642A (en) | 1974-06-04 | 1974-06-04 | Biological reagent |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE829828A (en) |
| GB (1) | GB1516642A (en) |
| SU (1) | SU639421A3 (en) |
| ZA (1) | ZA753568B (en) |
-
1974
- 1974-06-04 GB GB24660/74A patent/GB1516642A/en not_active Expired
-
1975
- 1975-06-03 BE BE156996A patent/BE829828A/en unknown
- 1975-06-03 SU SU752142156A patent/SU639421A3/en active
- 1975-06-03 ZA ZA3568A patent/ZA753568B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SU639421A3 (en) | 1978-12-25 |
| ZA753568B (en) | 1977-01-26 |
| BE829828A (en) | 1975-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE8900828L (en) | ANTIVIRAL AND IMMUNSTIMULATING PHARMACEUTICAL COMPOSITIONS AND PROCEDURES FOR PREPARING THEM | |
| ATE199373T1 (en) | AMINOALKYLMALEIMIDES AND HAPTEN AND ANTIGEN DERIVATIVES DERIVED THEREOF AS WELL AS CONJUGATES WITH PEPTIDES OR PROTEINS | |
| ES470961A1 (en) | Lipopeptides, process for their preparation and pharmaceutical compositions containing them. | |
| ES431601A1 (en) | Stable prostaglandin E group-containing formulation | |
| ES456541A1 (en) | N-phosphono methylene amino alkane phosphonic acid compounds, process of producing same, and method and compositions of using same | |
| GB1394416A (en) | Cyclopropanecarboxylates processes for producing them and compositions containing them | |
| ES438163A1 (en) | Conjugates of prostaglandins, analogs, formulations and their use | |
| GB1516642A (en) | Biological reagent | |
| CA1216793A (en) | Pge-type compositions encapsulated by acid isolated gelatin | |
| IE40977B1 (en) | Prostaglandin compositions | |
| IE40035L (en) | Modified gelatin blood plasma substitute. | |
| IT1116840B (en) | IMPROVEMENT IN PHARMACEUTICAL COMPOSITIONS CONTAINING PROSTAGLANDIN | |
| JPS52143217A (en) | Stable composition containing prostaglandi ne | |
| ES444926A1 (en) | 3-thiolated-7-acylamido-cephalosporanic acid derivatives processes for preparing them and pharmaceutical compositions 0mprising them | |
| SE7501083L (en) | ||
| GB1378068A (en) | Citric acid derivatives | |
| GB1511804A (en) | Cosmetic compositions containing deaminated collagen | |
| IL85029A (en) | Microcrystalline cis diammineplatinum(ii)complex of 1,1-cyclobutanedicarboxylic acid,its preparation and cytostatic pharmaceutical compositions containing it | |
| MX163817B (en) | PROCEDURE FOR PREPARING A PHOSPHONIC ACID ESTER BASED COMPOSITION FOR HAIR TREATMENT | |
| ES473090A1 (en) | A peptide and the salts thereof, processes for their preparation and compositions containing them. | |
| IL41868A (en) | Pharmaceutical preparations containing d-penicillamine | |
| US3885041A (en) | Antiinflammatory use of prostaglandins | |
| ES429119A1 (en) | Aluminium and/or magnesium salts of amino-acids | |
| JPS5578001A (en) | Polysaccharide-polypeptide combination having beta(1-3), (1-6) glucan structure and its preparation | |
| GB1520441A (en) | Di-(substituted alkyl) amino-benzenes with cytostatic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |